PK
Therapeutic Areas
HOOKIPA Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HB-200 | HPV16+ recurrent/metastatic head and neck squamous cell carcinoma | Phase 2 |
| HB-300 | Metastatic castration-resistant prostate cancer | Phase 1 |
| HB-400 | Chronic Hepatitis B (Functional Cure) | Preclinical |
| HB-500 | HIV (Therapeutic) | Preclinical |
| Arenavirus-based vaccine | Cytomegalovirus (CMV) Prophylaxis | Phase 1 |
Leadership Team at HOOKIPA Pharma
JA
Joern Aldag
Chief Executive Officer and Chairman of the Board
FH
Franz-Werner Haas, Ph.D.
Former Chief Executive Officer
IM
Igor Matushansky, M.D., Ph.D.
Chief Medical Officer
CM
Colleen Maisel
Chief Financial Officer
M(
Michael (Mick) Shepard, Ph.D.
Chief Scientific Officer
FA
Forrest Anthony, M.D., Ph.D.
Chief Technical Officer
TP
Timothy P. Reilly, Ph.D.
Chief Development Officer
AG
Andrés Gutiérrez, M.D., Ph.D.
Senior Vice President, Clinical Development
FB
Felix Baker
Board Member
BC
Bo Cumbo
Board Member